Tirzepatide (Mounjaro/Zepbound): Dual GLP-1/GIP — Complete Analysis
Scientific guide to Tirzepatide: dual GLP-1+GIP mechanism, SURMOUNT and SURPASS trial data, −22.5% body weight efficacy and FDA approval 2023.
Educational Content Only
The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
Mechanism of Action
Tirzepatide is an innovative dual agonism molecule, simultaneously acting on GLP-1 and GIP receptors (glucose-dependent insulinotropic polypeptide). Studies demonstrate that GIP agonism potentiates the insulinotropic and adipogenic response, resulting in greater weight reduction and glycemic control compared to pure GLP-1 agonists.
Data based on available scientific literature. Protocol individualization depends on qualified professional assessment.
Applications Described in the Literature
- ✓SURMOUNT-1 and -2: highest documented weight loss among approved agonists (up to 22.5% body weight)
- ✓SURPASS trials: superior glycemic control to semaglutide in type 2 diabetes
- ✓SURMOUNT-5: direct comparison with semaglutide 2.4 mg — 47% greater reduction with tirzepatide
- ✓Studies in metabolic fatty liver disease (MAFLD)
- ✓Research in heart failure with preserved ejection fraction (HFpEF)
Relevant Studies
SURMOUNT-1: Tirzepatide once weekly for obesity
2022 · PMID: 35658024
SURPASS-2: Tirzepatide versus semaglutide in type 2 diabetes
2021 · PMID: 34170647
SURMOUNT-5: Tirzepatide vs semaglutide 2.4 mg in obesity
2025 · PMID: 39893635
Premium
✓ DesbloqueadoProtocols Described in the Literature
SURMOUNT trial protocols use progressive titration with increments every 4 weeks. Escalation starts at 2.5 mg and advances in steps to 15 mg (maximum approved dose). Gastrointestinal tolerability guides the titration speed. Studies demonstrate that most participants tolerate the target dose of 10–15 mg after 20 weeks of titration.
Dose Ranges Observed in Studies
- ◆SURMOUNT titration: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (every 4 weeks)
- ◆Target dose in obesity studies: 10 mg and 15 mg/week
- ◆Approved dose for diabetes (SURPASS): 5 mg, 10 mg and 15 mg/week
- ◆Studies demonstrate that 10 and 15 mg doses produce similar weight loss, suggesting efficacy plateau
Effects Timeline (Literature)
SURMOUNT studies document ~5% weight reduction in the first 4 weeks (2.5 mg dose). Maximum loss achieved between 36–72 weeks. Glycemic response documented from 4 weeks. In SURMOUNT-5, statistically significant difference vs semaglutide observed from week 8.
Documented Associations
- ↗Semaglutide: direct comparison available; tirzepatide demonstrated superiority in weight loss in SURMOUNT-5
- ↗Metformin: documented combination in SURPASS studies with additive glycemic benefit
- ↗SGLT-2 inhibitors: plausibility of complementary cardiovascular and renal benefit described in reviews
Monitoring Described in Studies
- ⊕Body weight: weekly assessment recommended in efficacy studies
- ⊕HbA1c: quarterly assessment in diabetes studies
- ⊕Lipase and amylase: pancreatic safety monitoring in trials
- ⊕Heart rate: mild increase (~2–3 bpm) documented, less than semaglutide
Clinical Observations from Studies
- ℹApproved by FDA (Mounjaro for T2D, Zepbound for obesity) and ANVISA as Mounjaro
- ℹWeight loss superior to all approved drugs up to 2025, except bariatric surgery
- ℹAdverse effect profile similar to semaglutide: predominance of gastrointestinal symptoms
- ℹWeight regain documented upon discontinuation: reinforces the chronic nature of treatment
All information above is exclusively educational, based on scientific literature. It does not constitute medical prescription. Individualization of any protocol requires evaluation by a qualified healthcare professional.
Frequently Asked Questions
Is Tirzepatide more effective than Semaglutide?▼
In indirect comparison, Tirzepatide (SURMOUNT-1) showed mean weight loss of 22.5% vs 14.9% with Semaglutide (STEP 1). SURPASS-2 directly confirmed Tirzepatide superiority.
⚠️ Medical Disclaimer: The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.